POPULARITY
4 episodes with systemic sclerosis
9 episodes with systemic sclerosis
2 episodes with systemic sclerosis
4 episodes with systemic sclerosis
2 episodes with systemic sclerosis
9 episodes with systemic sclerosis
2 episodes with systemic sclerosis
2 episodes with systemic sclerosis
2 episodes with systemic sclerosis
In this episode, we dive into a fascinating and often overlooked aspect of rheumatology: complications from diabetes that can mimic rheumatic diseases. Dr. Schiopu kicks off the discussion by shedding light on Diabetic Myonecrosis, a painful muscle condition that can be easily mistaken for other rheumatic disorders. We then explore Scleroderma, a skin-thickening muscle disorder that resembles systemic sclerosis (SSC) but has distinct underlying mechanisms. Dr. Schiopu shares invaluable insights on how to approach complex rheumatology consults in the hospital, emphasizing the importance of thoughtful diagnostic reasoning. She also discusses why sometimes the best approach in medicine is to avoid unnecessary tests and treatments, prioritizing patient care and accuracy in diagnosis.
In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks with Dr. Victoria Flower about Gastrointestinal (GI) issues in Systemic SclerosisThis episode is part one of a two part series, with this first episode focussing on Upper GI issues and part two the Lower GI tract. We begin with a brief introduction around the whole topic and run through issues such as reflux, difficulty swallowing, and similar symptoms that someone with Systemic Sclerosis might experience. Vicky then talks about treatment options and self-management approaches.Useful Links:Dysphagia (swallowing problems) - NHSHeartburn and acid reflux - NHSConnect further with us:Have questions or thoughts about our information Podcast library? Interested in joining BIRDs patient research panel? Email Mel at ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!The Patient and Public Engagement Programme is supported by hands-off sponsorships from Eli Lilly and Company Limited, UCB and Amgen -all of whom have provided grant funding but who have were not involved in the development, content or editorial control of this podcast, nor the subsequent review and approval of these materials or general running of the patient and public engagement programme.We would also like to thank The Arnold Clark Community Fund, The Cumber Family Charitable Trust, Medlock Charitable Trust, The Ray Harris Charitable Trust and The Hospital Saturday Fund.Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit the BIRD website to sign up for news.
In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks with Dr. Victoria Flower about Gastrointestinal (GI) issues in Systemic SclerosisThis episode is part two of a two part series. This time we focus on the Lower GI talking about the movement of food through the lower GI tract and common issues one might experience such as a sluggish bowel and bacterial overgrowth and symptoms like bloating and diarrhea. Vicky also talks us through treatment and self-management options, including dietary adjustments.Useful Links:Dysphagia (swallowing problems) - NHSHeartburn and acid reflux - NHSHow to help a weak bladder - NHSGastrointestinal Tract Involvement in Systemic Sclerosis (SSc) | SRUK Connect further with us:Have questions or thoughts about our information Podcast library? Interested in joining BIRDs patient research panel? Email Mel at ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!The Patient and Public Engagement Programme is supported by hands-off sponsorships from Eli Lilly and Company Limited, UCB and Amgen -all of whom have provided grant funding but who have were not involved in the development, content or editorial control of this podcast, nor the subsequent review and approval of these materials or general running of the patient and public engagement programme.We would also like to thank The Arnold Clark Community Fund, The Cumber Family Charitable Trust, Medlock Charitable Trust, The Ray Harris Charitable Trust and The Hospital Saturday Fund.Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit the BIRD website to sign up for news.
Qu'est-ce que le VEDOSS et pourquoi ce programme a-t-il été développé ? Quels avantages apporte un diagnostic très précoce pour la gestion de la sclérodermie systémique ? Quels examens peuvent aider le rhumatologue à diagnostiquer un cas de VEDOSS ? Quelles sont les découvertes récentes en recherche sur le VEDOSS ? Le Pr Marie-Elise Truchetet, rhumatologue au CHU de Bordeaux, nous éclaire sur ce sujet. Liens d'intérêt : Abbvie, Pfizer, Lilly, UCB, Novartis, Boehringer. L'équipe : Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud-Listrat, Dr Céline Vidal, Dr Sophie Hecquet. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer
In this pod Dr Stephanie Gall speaks with Professor Marina Anderson and Dr Sarah Tansley. Listen in to better understand how to interpret antibody results in patients with systemic sclerosis, myositis and their overlaps. They'll cover the clinical patterns seen and how to weed out false positive results.Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.
In this episode we are joined again by Rheumatology Specialist Registrar Dr Aine Connerton to discuss Systemic Sclerosis (scleroderma) as a potential station in the Irish MRCPI Part II clinical exam. We discuss the approach the distinctions between systemic sclerosis or scleroderma, CREST, and Raynaud's Syndrome, physical findings, a differential diagnosis, investigations and management. We then go on to briefly talk through some potential follow-up questions. This podcast is supported by Pastest and their excellent online education resource to help candidates sit their clinical exams. Sign up to Pastest MRCP Clinical revision resource via our affiliate link below: https://www.awin1.com/cread.php?awinmid=46017&awinaffid=1651835&campaign=MRCPi+Bedisde&ued=https%3A%2F%2Fwww.pastest.com%2Fmrcp-part-1%2F For Irish based candidates you can apply to claim back the cost through the training support scheme (up to date as of July 2023) Consultant supervisor Professor Declan Byrne, consultant physician St James's Hospital, Dublin Show music by Stepping on Lego - email: steppingonlegoband@gmail.com - socials: @steppingonlego_ Get in touch with us by email mrcpibedside@gmail.com or social media @mrcpibedside Good luck!
In this episode we are joined again by Rheumatology Specialist Registrar Dr Aine Connerton to discuss Systemic Sclerosis (scleroderma) as a potential station in the Irish MRCPI Part II clinical exam. We talk through a case of rheumatoid arthritis - the physical findings, a differential diagnosis, investigations and management. We then go on to briefly talk through some potential follow-up questions including monitoring on biologic therapy, extra-articular manifestations, and causes of anaemia in RA. This podcast is supported by Pastest and their excellent online education resource to help candidates sit their clinical exams. Sign up to Pastest MRCP Clinical revision resource via our affiliate link below: https://www.awin1.com/cread.php?awinmid=46017&awinaffid=1651835&campaign=MRCPi+Bedisde&ued=https%3A%2F%2Fwww.pastest.com%2Fmrcp-part-1%2F For Irish based candidates you can apply to claim back the cost through the training support scheme (up to date as of July 2023) Consultant supervisor Professor Declan Byrne, consultant physician St James's Hospital, Dublin Show music by Stepping on Lego - email: steppingonlegoband@gmail.com - socials: @steppingonlego_ Get in touch with us by email mrcpibedside@gmail.com or social media @mrcpibedside Good luck!
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
BSR has published an update to the systemic sclerosis guideline, expanded to include paediatric and adolescent patients for the first time. Join guideline working group Chair, Prof Chris Denton, members John Pauling, Bridget Griffiths and Clare Pain, and expert by experience member, Sue Farrington, in a roundtable discussion hosted by Prof Ernest Choy.Read the full guideline and download the summary pdf here. Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.
How many patients maintain weight loss 1 year after discontinuing semaglutide or liraglutide? Find out about this and more in today's PeerDirect Medical News Podcast.
Systemic Sclerosis (SSc) is a painful and debilitating disease that our patients suffer from. However, a newly published study has concluded that there are some self-management interventions patients can engage with that have shown to improve fatigue, particularly for those newly diagnosed with SSc. Today, we review the procedures, interventions, results and conclusions of this study, titled: Effects of a Resilience-Building Energy Management Program on Fatigue and Other Symptoms in Systemic Sclerosis: A Randomized Controlled Trial, along with two of its authors, Dr. Susan L Murphy and Ms. Mary Alore, and how your patients can benefit from its lessons.
Expert researcher and clinician, Dr. Elana Bernstein, is our guest this week as we dive into lung disease brought on by Systemic Sclerosis (SS). We discuss symptoms, diagnosis, how systemic sclerosis affects the lungs, including pulmonary hypertension and interstitial lung disease. Dr. Bernstein, who has dedicated her career to improving patient outcomes in systemic sclerosis, explains her approach to screening for lung disease, plus the latest research and questions that need to be answered.
Welcome back to “Journals”! Our topic of discussion today comes from the manuscript Anti-Gephyrin Antibodies: A Novel Specificity in Patients With Systemic Sclerosis and Lower Bowel Dysfunction and our guest today is the study's first author, Dr. Zsuzsanna McMahan. The study recognizes that the enteric nervous system (ENS) regulates the gastrointestinal (GI) function, which is commonly impaired in those who suffer from systemic sclerosis (SSc). Dr. McMahan and her team's objective for this study was “to identify novel anti-ENS autoantibodies with an aim to clinically phenotype SSc GI dysfunction”. We sit down with Dr. McMahan and discuss the study's methods and discoveries. Plus, her experience transitioning from a junior to an independent investigator and what advice she can offer our young listeners for the journey along the way.
Today's guest is Dr. Duncan Moore from the Northwestern Scleroderma Center. Our topic today is classification and diagnosis of scleroderma. There is a classification point system that rheumatologists can use to help determine diagnosis. Dr. Moore talks through the classification system. We discuss the differences between diffuse cutaneous systemic Sclerosis and limited cutaneous systemic Sclerosis. We end with Dr. Moore and the scleroderma center offering to coordinate with your local rheumatologist to help with diagnosis and treatment.1. The 2008 paper by Koenig et al. which describes various rates of progression from Raynaud's phenomenon to systemic sclerosis. Free to access. [https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.24038]2. The 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis. Free to access. [https://ard.bmj.com/content/72/11/1747.long]
Professor Doron Rimar joins Dr Cristiana Sieiro Santos to discuss their article, which retrospectively compares the outcomes of SSc patients who underwent AHSCT to patients who met the eligibility criteria for AHSCT but received upfront combination therapy with MMF and rituximab.Listen now to hear the findings and what this means for future clinical practice! You can read this article [https://doi.org/10.1093/rheumatology/kead457] in Rheumatology.Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram. Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
This episode covers systemic sclerosis.Written notes can be found at https://zerotofinals.com/medicine/rheumatology/systemicsclerosis/ or in the rheumatology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.
This week we welcome our next guest, Dr. John D. Pauling to ‘Journals'. Dr. Pauling is the senior author of the manuscript “Assessment of the Systemic Sclerosis-Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short Form Development”, which endeavored to “develop, refine and score a novel patient-reported outcome instrument to assess the severity and impact of Raynaud's Phenomenon (RP) in Systemic Sclerosis (SSc)”. In this episode, we discuss the challenges associated with measuring one of the most common disease manifestations of scleroderma, Raynaud's, and how the Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) questionnaire was harmonious in the paper's results and final conclusions.
DO YOU KNOW what TOXINS you are EXPOSED to Daily, and HOW to AVOID them? AND that there are MANY TOXINS that have been shown to INCREASE your RISK of AUTOIMMUNE Disease? (Think Thyroid problems like HASHIMOTOS, Lupus, Many types of Arthritis, Systemic Sclerosis, Sjogren's and many others like Type 1 Diabetes!)*This podcast will take You on a deep dive to the common TOXINS that are literally HIDING IN PLAIN SIGHT and the ones you may be exposed to and how to AVOID THEM!Dr. Thomas Hemingway will discuss SIMPLE DAILY HACKS to REDUCE your exposure that are largely FREE and NOT time consuming. These Simple Strategies will REDUCE your toxic load and help you potentially AVOID many common diseases including the AUTO-IMMUNE ones that are commonly implicated in or contributed to from toxin exposure.*MY NEW BOOK! https://www.amazon.com/PREVENTABLE-Powerful-Practices-Disease-Unshakeable/dp/B0C6C16VCS/ref=cm_cr_arp_d_product_top?ie=UTF8*THRIVE COMMUNITY! PERSONAL Q+A with Dr. Hemingway: https://thomashemingway.podia.com/thomas-hemingway-community *FREE NEWSLETTER: https://view.flodesk.com/pages/619eb66f117f2e0a9bdc5993*HEALTH OPTIMIZATION Courses➡️ https://thomashemingway.podia.comFOLLOW ALONG:Instagram: https://www.instagram.com/drthomashemingway/ Facebook: https://www.facebook.com/thomashemingwaymdTwitter: https://twitter.com/doc_hemingwayLinkedIn: https://www.linkedin.com/in/thomashemingway/DISCLAIMER: https://docs.google.com/document/d/1r3fz8KZE6dVhJHo4V9DHGayU-zmPHtAs31JhokQgJKA/edit?usp=sharing
This episode's PACES classic topic is Systemic sclerosis, brought to you with a smile by Dr Sam Williams (as usual) and Dr John Pauling, consultant rheumatologist at North Bristol NHS Trust. This episode covers all the key elements of Systemic sclerosis as it might be presented in a PACES style scenario and is surely essential listening for your PACES preparation.> > Sign up for Pastest HERE! <
The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment - doi.org/10.3899/jrheum.220459 Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis - doi.org/10.3899/jrheum.221113 Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases - doi.org/10.3899/jrheum.221014 Myocarditis in Patients With Idiopathic Inflammatory Myopathies: Clinical Presentation and Outcomes - doi.org/10.3899/jrheum.220989 Integrating PROMIS Measures in a Treat-to-Target Approach to Standardize Patient-Centered Treatment of Rheumatoid Arthritis - doi.org/10.3899/jrheum.2022-1176
In today's episode, Dr Innocent Munzeiwa joins us again to walk us through Systemic sclerosis and its management.
The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. Understanding Differences in Patient Descriptions of Rheumatoid Arthritis Flares Using OMERACT Core Domains - doi.org/10.3899/jrheum.211409 Cigarette Smoking Increases the Prevalence of Hip Joint Involvement in Ankylosing Spondylitis: A Real-World Case-Control Study - doi.org/10.3899/jrheum.220609 A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis - doi.org/10.3899/jrheum.220990 Patient Care Pathways for Pregnancy in Rare and Complex Rheumatic Diseases: Results From an International Survey - doi.org/10.3899/jrheum.220773 Changes in Service Delivery and Access to Rheumatologists Before and During the COVID-19 Pandemic in a Canadian Universal Healthcare Setting - doi.org/10.3899/jrheum.220658
CME credits: 1.75 Valid until: 31-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-screen-for-pah-in-systemic-sclerosis-patients/15565/ In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
CME credits: 1.75 Valid until: 31-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/why-should-we-screen-for-pah-in-systemic-sclerosis-patients/15564/ In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Our guest this week, Dr. Alexandru-Emil Matei, is the first author of a study that endeavored to evaluate immune cell activation in scleroderma. His study, written for the completion of his medical training in Romania is titled: “Identification of a Distinct Monocyte-Driven Signature in Systemic Sclerosis Using Biophysical Phenotyping of Circulating Immune Cells“ (recently published in “Arthritis & Rheumatology”) performed biophysical phenotyping of circulating immune cells by employing a novel high-throughput method called ‘real-time fluorescence and deformability cytometry' (RT-FDC). Dr. Matei's study attempts to demonstrate that RT-FDC measures can “detect changes in the biophysical properties of individual immune cell populations in SSc patients”. If demonstrated, then RT-FDC may be used as another tool in identifying pathologic immune cell activation, being that immune cells like monocytes play a major role in systemic sclerosis (SSc).
This podcast explores hematopoietic stem cell transplant in diffuse cutaneous systemic sclerosis (dcSSc) and the potential role of FCR001, an investigational allogeneic cell therapy. We are pleased to be joined by leading sclerosis expert Dinesh Khanna MD, MSc. Dr. Khanna is the Sclerosis Program Director at University of Michigan, USA, Dr. Khanna discusses the symptoms, severity, and progressiveness of sclerosis, focusing on dcSSc. Dr. Khanna further explores the current treatment options, the unmet medical need, and the future of FCR001 and allogeneic stem cell transplants. This podcast is funded and developed by Talaris Therapeutics, Inc. Talaris Therapeutics is a late-clinical stage cell therapy company that is developing an investigational allogeneic stem cell therapy.
Connective Tissue Diseases (CTD) are disorders that exhibit autoimmune-meditated damage to various organs, one type of CTD is Scleroderma, also known as Systemic Sclerosis. Pulmonary Fibrosis is a lung manifestation that can develop in patients with Scleroderma. In this episode of “Spotlight on Pulmonary Fibrosis in Connective tissue Disease” we will meet the scleroderma patient Michaela Linkova from Czech Republic as she talks about her journey towards diagnosis. We also hear from Dr. Katarzyna Pershina, a radiologist from Russia, and Prof. Czirják László István, a rheumatologist from Hungary, who discuss how to recognise the early signs and symptoms; and explain what are the tests and examinations that used to diagnose and monitor scleroderma in patients.
#potobiomodulation #mentalhealth #vielight Dr. Lew Lim discusses photobiomodulation with Jay Gunkelman and Pete Jansons. Other Topics discussed PTSD and photobiomodulation use with Veterans, Brain Fog, ADHD, Autism, Alzheimer's, photobiomodulation and its effect on increasing Gamma, Default Mode Network, Alpha Theta Training, Peak Performance, Ketamine, Systemic Sclerosis, Parkensons, Dementia Cold Laser Therapy, Chronic Pain Vielight combines science and engineering ingenuity to develop unique photobiomodulation devices. Their goal is to improve one's quality of life by continuously pushing the boundaries through innovation of the delivery of light energy into the brain and inner systems. Vielight is committed to exploring new theories and research that lead to the development of home-use personal devices that are safe, practical and effective for everyone. To achieve this end, we collaborate with knowledge leaders and major universities world-wide. --- Send in a voice message: https://anchor.fm/neuronoodle/message Support this podcast: https://anchor.fm/neuronoodle/support
Connective Tissue Diseases (CTD) are disorders that exhibit autoimmune-meditated damage to various organs, one type of CTD is Scleroderma, also known as Systemic Sclerosis. Pulmonary Fibrosis is a lung manifestation that can develop in patients with Scleroderma. In this episode of “Spotlight on Pulmonary Fibrosis in Connective tissue Disease” we will meet the scleroderma patient Michaela Linkova from Czech Republic as she talks about her journey towards diagnosis. We also hear from Dr. Katarzyna Pershina, a radiologist from Russia, and Prof. Czirják László István, a rheumatologist from Hungary, who discuss how to recognise the early signs and symptoms; and explain what are the tests and examinations that used to diagnose and monitor scleroderma in patients.
In this special episode of Journeys through Pulmonary Fibrosis we a proud to collaborate with FESCA. Sue Farrington, President of the Federation of European Scleroderma Associations (FESCA) and Chief Executive of Scleroderma and Raynaud's UK, speaks with Ilaria, who lives with Scleroderma and is Vice Chair of FESCA, and her husband Sergio. Ilaria was diagnosed with Scleroderma in 1996, and lung involvement in 1997, just three months after her relationship with Sergio began. They discuss their experience of scleroderma with lung involvement, how it has affected their relationship, how it has affected them as individuals, and what advice they would give their younger selves.
CME credits: 1.00 Valid until: 23-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/systemic-sclerosis-associated-pah-a-complex-patient-set/13857/ tbd
CME credits: 1.00 Valid until: 23-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/systemic-sclerosis-associated-pah-a-complex-patient-set/13857/ tbd
In this podcast, Dr. Truchetet discusses her work on the role of innate lymphoid cells in the fibrotic processes in systemic sclerosis (SSc) patients. The group of Dr. Truchetet found that ILC2 are crucial mediators of skin fibrosis in SSc and that combined treatment of patients with TGFb inhibitors and IL-10 might be an attractive new therapeutic approach in SSc. Read the full paper on the ARD website: https://ard.bmj.com/content/80/12/1594 Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page (https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059).
Today we sit down with Caitlin Nelson as she shares her powerful story into recovery. Caitlin is currently a staff member at Elevate Addiction Services and works in our Detox facility. Caitlin walks us through the perils of addiction and how she found herself on the other side, sober and happy. Enjoy the show! Don't forget to like, subscribe, share, tell a friend if you found value in the show. We appreciate your support in listening and being part of the solution! Make sure to follow us on social - @elevateaddictionservices @angie.at.elevate You can find us on the web -www.elevaterehab.org With these current times, if you know anyone or are struggling with mental health/addiction yourself please reach out. There is help and there is hope, and there are solutions to these problems. Speak to our Admission Counselors at 831-740-8298 You don't ever want to miss a podcast, so make sure you subscribe here!
Both subtypes (limited cutaneous including CREST syndrome and diffuse cutaneous) of systemic sclerosis are discussed with workup and management point followed by discussion of important complications (including scleroderma renal crisis)
Dr Highland provides an overview of systemic sclerosis and associated interstitial lung disease, including symptoms and diagnosis, who's at risk, and new and upcoming treatments for this complex disease.
Dr Elena Netchiporouk of the McGill University Health Centre joins Kirk Barber to discuss her article in the March/April issue of the Journal of Cutaneous Medicine and Surgery titled: "Towards Understanding of Environmental Risk Factors in Systemic Sclerosis." As Kirk notes at the start of the interview, "It sounds like a very dry subject, but when I sat down and went through the article in detail, some really fascinating things come up," and with that, their journey through the background and findings of the article begins. It's a subject that Dr Netchiporouk describes as a passion, and it includes research that dates back to 1914. Dr. Elena Netchiporouk is an assistant professor of dermatology at the McGill University Health Centre and the Director of Undergraduate Studies for Dermatology at McGill. You can find Dr Netchiporouk's article in JCMS below. It is available free for three weeks after this interview is posted: https://journals.sagepub.com/doi/abs/10.1177/1203475420957950 JCMS Author Interviews is produced by David McGuffin of Explore Podcast Productions in Ottawa. Our theme music was composed by Lee Rosevere.
The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. This month's Editor's Picks spotlight interview is with Dr. Ibrahim Almaghlouth. This month's selections also include: Almaghlouth, et al: Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus - https://doi.org/10.3899/jrheum.200254 Faye, et al: Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City - https://doi.org/10.3899/jrheum.200989 Grosse, et al: Evaluation of Bone Erosions in Rheumatoid Arthritis: The Ultrasound Score for Erosions Versus the Modified Sharp/van der Heijde Score for Erosions - https://doi.org/10.3899/jrheum.200286 Liew, et al: Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study - https://doi.org/10.3899/jrheum.200188 van Leeuwen, et al: Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis - https://doi.org/10.3899/jrheum.191331 To read the full articles visit www.jrheum.org. Music by David Hilowitz
Ben Konkin is back! Ben first joined us in episode 16 and left us inspired and reflective. We needed to have this warrior back on the show, but this time with his fabulous wife, Julia! Ben was diagnosed with Scleroderma, or Systemic Sclerosis, in 2018 that nearly took his life. Scleroderma is a rare and life-threatening autoimmune disease, which slowly hardens your soft tissue, leading to a multitude of symptoms and other related diseases. Ben continues to bravely speak out about his journey and Julia shines a bright light on those who don't get nearly enough of the credit they deserve... the caregivers!We get to learn about Ben and Julia's story, as a strong and unwaveringly supportive couple who are the perfect example of how love wins through disease and hardships. Just like in our 1st chat with Ben, there are many wise words shared and life lessons learned that left us feeling moved and contemplative.Also, Ben & Julia have a not-for-profit foundation, the Scleroderma Network of Canada Foundation. A link to this foundation, which helps bring those affected by Scleroderma together in order to fight this disease with as much arsenal as possible, is below.“You have a choice to live in anger, frustration and self deprecation OR you can put a smile on your face and do everything you can to make it to the next day”. — Ben Konkin"This year I choose happiness." -- Julia KonkinBen's LINKS:Scleroderma Network Website & How to DonateInstagram (@sclerodermanetwork)Getting Jewcy Links:Watch This Episode on YouTubeInstagram (@getting_jewcy)Facebook (@gettingjewcy)
Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.
Live from ACR: A Conversation on Systemic Sclerosis-Associated Interstitial Lung Disease
Ben Konkin is a warrior. This episode (#16) left Rachel and Hiiro inspired, reflective and a little verklempt. Ben was diagnosed with Scleroderma, or Systemic Sclerosis (a rare and life-threatening autoimmune disease) in 2018 that nearly took his life not too long ago. Ben bravely opens up about his disease and his journey, and speaks about his new not-for-profit foundation, the Scleroderma Network of Canada Foundation. We can't say enough amazing things about this man. We learned so much about this disease that affects more North Americans than we imagined. Ben also was full of wise words and lessons for ANYONE to live by. We love you Ben!“You have a choice to live in anger, frustration and self deprecation OR you can put a smile on your face and do everything you can to make it to the next day”. — Ben KonkinBEN'S LINKS:Scleroderma Network Website & How to DonateInstagram (@sclerodermanetwork)GETTING JEWCY LINKS:Instagram (@getting_jewcy)Facebook (@gettingjewcy)
FDA 批准卡那单抗用于治疗成人Still病Lancet 苏金单抗与阿达木单抗治疗银屑病关节炎的头对头比较Arthri & Rheumatol重组腺苷脱氨酶可改善系统性硬化症模型的纤维化卡那单抗（canakinumab）上周一的心脏科专题中，我们聊到了冠心病的抗炎治疗最新进展，目前研究热点集中在IL-1β单克隆抗体卡那单抗和秋水仙碱。今天我们来聊一聊卡那单抗在免疫科中的应用。卡那单抗（canakinumab）最初于2009年被FDA批准用于治疗Cryopyrin相关周期性综合征（CAPS）、全身型幼年特发性关节炎以及三种少见的周期性发热综合征；2020年6月，卡那单抗被FDA批准用于治疗成人Still病。《卡那单抗用于治疗成人Still病以减少关节炎的表现：2期临床试验》Annals of Rheumatic Diseases，2020年8月 (1)这项多中心、双盲、随机、安慰剂对照试验，旨在评价其治疗成人Still病的有效性和安全性。研究纳入19名多关节受累的成人Still病患者，随机给予卡那单抗和安慰剂治疗。基线时，卡那单抗组和安慰剂组的平均疾病活动评分为5.4和5.3。在卡那单抗组中，61%的患者达到30%应答率，50%的患者达到50%应答率，28%的患者达到70%应答率；而对照组仅为20%、6.7%和0%（p=0.033，0.009和0.049)。卡那单抗组的两名患者经历了严重的不良事件。结论：卡那单抗治疗可改善多项成人Still病的疗效指标。银屑病性关节炎银屑病关节炎（psoriatic arthritis，PsA）是一种与银屑病有关的炎症性肌肉骨骼疾病。主要表现为受累关节疼痛和僵硬，可同时累及周围关节和中轴关节，常呈非对称性分布。70%的关节炎就诊时有银屑病病史，80-90%伴有甲病变。实验室检查没有特征性的变化，类风湿因子（RF）、抗核抗体（ANA）和抗瓜氨酸肽抗体（ACPA）大多呈阴性。《荟萃分析：银屑病关节炎关节外表现的患病率》Rheumatology，2020年9月 (2)研究的目的是评价银屑病关节炎关节外症状的流行情况（肌腱炎、指炎、指甲疾病、葡萄膜炎和炎症性肠病），及其对纵向疾病结局的影响。研究纳入65项研究，共计163 299例银屑病关节炎患者。在进行报道的文献中，肌腱炎平均发病率为30%，指炎平均发病率为25%，甲疾病发病率为60%，葡萄膜炎为3.2%，炎症性肠病3.3%。其中，合并指炎的患者影像学进展的可能性增加。结论：银屑病关节炎患者中，常合并肌腱炎、指炎和甲病；而葡萄膜炎和炎症性肠病不常见。《真实世界：银屑病或银屑病关节炎患者严重感染的风险》Annals of Rheumatic Diseases，2020年2月 (3)研究的目的是使用IL-17、IL-12/23或肿瘤坏死因子（TNF）抑制剂，是否与银屑病或银屑病关节炎患者严重感染风险的增加有关。研究共包括11560个新的治疗事件，9264人年的随访。研究共发现190例严重感染（占治疗期的2%），IL-17和TNF抑制剂的感染发生率相似，而IL-12/23抑制剂则明显降低（风险比0.59）。在曾经使用过生物制剂的患者中，各组感染风险无差异。结论：相对于TNF和IL-17抑制剂，IL-12/23抑制剂可以降低银屑病或银屑病关节炎患者的严重感染的风险。《纵向队列研究：银屑病性关节炎的DAPSA、颈动脉斑块和心血管事件》Annals of Rheumatic Diseases，2020年11月 (4)研究的目的是评价反映银屑病关节炎炎症成分的银屑病关节炎的疾病活动评分（DAPSA）是否能够预测心血管事件，而不依赖于传统的心血管危险因素和亚临床颈动脉粥样硬化。研究纳入189例银屑病关节炎患者，平均年龄48.9岁。平均9.9年的随访后，较高的银屑病关节炎的疾病活动评分与心血管事件的风险增加显著相关（风险比 1.04， p=0.009），在多变量模型中调整所有心血管风险后，这种关联仍然有统计学意义。亚组分析中，调整其他心血管风险后，颈动脉斑块与发生CV事件的风险增加显著相关（风险比 3.42）。结论：较高的DAPSA和CP的存在可以独立预测银屑病关节炎患者的心血管事件事件，这种风险不依赖于传统的心血管疾病风险。小羽点评：银屑病性关节炎不仅累及皮肤、关节，还可能增加感染和心血管疾病的发生风险，在临床实践中，需要对银屑病关节炎的患者进行多个系统的功能进行跟踪和随访。银屑病关节炎的治疗银屑病关节炎中，外周关节炎常使用NSAID治疗；若效果不佳，常采用传统改变病情的抗风湿药物（DMARD），如甲氨蝶呤（MTX）、来氟米特（LEF）；若多个关节侵蚀及功能受限，建议使用生物性DMARD，如TNF抑制剂为一线治疗（依那西普、阿达木单抗、英夫利西单抗、塞妥珠单抗和戈利木单抗）。一种TNF抑制剂无效时，可换用另一种TNF抑制剂；两种TNF抑制剂无效时，可使用IL-17抑制剂（苏金单抗、依奇珠单抗）、IL-12/23抑制剂（优特克单抗）、T细胞共刺激调节因子（阿巴西普）、JAK抑制剂（托法替尼）。累及骶髂关节和脊柱关节、附着点炎时，通常不推荐使用传统DMARD。银屑病关节炎患者一般应避免使用糖皮质激素，因为可能增加红皮病或脓疱型银屑病的几率。《回顾性队列研究：传统合成抗风湿药治疗银屑病性关节炎中，单药保留甲氨蝶呤优于柳氮磺胺吡啶》Rheumatology，2020年8月 (5)比较传统合成抗风湿药物的疗效和使用时间的研究有限，此研究的目的是比较一线传统合成抗风湿药物单药治疗的银屑病关节炎的药物保留和药物保留的预测因子。文章回顾性的研究了首次使用传统抗风湿药物作为单一药物治疗银屑病关节炎的187例患者，主要终点是治疗失败、停止用药或添加另一个抗风湿药物的时间。患者中单药使用甲氨蝶呤共163人，单药使用柳氮磺胺吡啶共21人，平均药物保留事件为31.8个月。其中甲氨蝶呤平均使用34.5个月，柳氮磺胺吡啶平均使用12.0个月（P =0.016）。使用甲氨蝶呤的患者中，随着年龄增长药物保留率逐渐增加。治疗失败的主要原因是无效(52%)和副作用(28%)。结论：在临床实践中，甲氨蝶呤单药治疗银屑病关节炎优于柳氮磺胺吡啶。《GO-DACT研究：治疗银屑病关节炎患者的指炎方面，戈利木单抗联合甲氨蝶呤优于单用甲氨蝶呤》Annals of Rheumatic Diseases，2020年4月 (6)戈利木单抗是一种抗肿瘤坏死因子α单抗，研究的目的是评价戈利木单抗联合甲氨碘呤和单用甲氨蝶呤治疗银屑病性关节炎指炎的疗效。这个多中心、随机、双盲、安慰剂对照、平行设计的3b期试验中，银屑病关节炎伴有活动性指炎的患者被分配到戈利木单抗或安慰剂组，两者均与甲氨蝶呤联合使用。24周后，与甲氨蝶呤单药治疗相比，戈利木单抗联合甲氨蝶呤显著改善指炎的临床症状（指炎严重程度评分变化分别为5和2，p = 0.026）。联合治疗组的指炎严重程度评分改善50%或70%的患者和Leeds指炎指数改善20%、50%或70%的患者比例显著高于单用甲氨蝶呤的患者。结论：戈利木单抗联合甲氨蝶呤作为一线生物抗风湿治疗银屑病指炎优于甲氨蝶呤单药治疗。《荟萃分析：生物制剂对银屑病关节炎患者外周关节影像学进展的影响》Rheumatology，2020年11月 (7)研究的目的是确定生物制剂在预防银屑病关节炎患者、外周关节影像学进展中的有效性。研究包括11项临床试验，涉及5382名患者，9种药物和18种治疗方法。与安慰剂相比，接受生物制剂的患者更有可能实现影像学无进展（优势比2.40，其中TNF抑制剂的优势比 2.94，IL抑制剂的优势比 2.15，阿巴西普的优势比 1.54）。生物制剂显著降低了外周关节影像学进展的风险（影像学进展评分平均下降-2.16，其中TNF抑制剂下降 -2.82，IL抑制剂下降 -1.60，阿巴西普下降 -0.40。生物制剂联合甲氨蝶呤的方案，并不优于单一生物制剂治疗的效果；尤特克单抗和苏金单抗的疗效，不受先前抗TNK治疗的影响。结论：与安慰剂相比，生物制剂可能在骨侵蚀和关节间隙狭窄方面延缓银屑病关节炎患者的影像学进展。甲氨蝶呤似乎没有额外的获益；先前的抗肿瘤坏死因子治疗似乎不会影响IL抑制剂的治疗效果。上一次的节目介绍了IL-17抑制剂（苏金单抗、依奇珠单抗）最近刚刚被FDA批准用于治疗中轴型脊柱关节炎，今天来和大家聊一聊IL-17A单抗在银屑病关节炎中的应用，以及比较这两个药物和肿瘤坏死因子抑制剂阿达木单抗的头对头研究。《Future 5研究：苏金单抗治疗银屑病性关节炎的3期研究结果》Rheumatology，2020年6月 (8)研究目的是评估苏金单抗治疗银屑病性关节炎52周后患者的影像学进展。纳入的银屑病性关节炎参与者，既往没有治疗过、或者TNF-α抑制剂无效，被随机分入苏金单抗 300mg组、150mg组、150mg无负荷给药组或安慰剂组，前4周q1w负荷给药，4周后q4w给药。其中300mg组有91.8%的患者52周后，没有出现影像学进展；在150mg组和150mg无负荷给药组中，这里比例分别是85.2%和87.2%。苏金单抗 300mg组、150mg组和150mg无负荷给药组中，影像学vdH-mTSS评分的随机斜率为-0.18、0.11和-0.20。临床疗效持续稳定，52周内没有报告新的或意料之外的安全事件。结论：苏金单抗 300mg、150mg和150mg无负荷剂量组，治疗银屑病性关节炎显示出持续稳定的低进展率。《SPIRIT-P1研究：依奇珠单抗治疗活动性银屑病关节炎患者的III期临床试验3年结果》Rheumatology，2020年2月 (9)研究的目的是评估长达156周的依奇珠单抗（IL-17A单抗）治疗银屑病关节炎的安全性和有效性。银屑病关节炎患者被随机分配到安慰剂组、阿达木单抗或依奇珠单抗q2w或q4w组。在第24周时，阿达木单抗和安慰剂组的患者被重新随机分配到依奇珠单抗q2w或q4w组，并继续延长治疗至第156周，共243例患者完成了为期3年的研究。依奇珠单抗q2w组患者治疗紧急和严重不良事件的发生率分别为38.0%和5.2%，依奇珠单抗q4w组患者为38.1%和8.0%。156周时，两组患者ACR响应≥20%的比例占69.8%和62.5%；响应≥50%的比例为51.8%和56.1%，响应≥70%的比例为33.4%和43.8%。银屑病面积和严重程度指数（PASI）缓解75%的占（63.5%和69.1）；缓解90%的展51.2%和64.5；缓解100%的占43.6%和60.5%。直至156周，在q2w组中的61%和q4w组中的71%的患者，影像学进展得到抑制。结论：依奇珠单抗治疗156周后，其安全性与之前的报道保持一致，并且观察到银屑病关节炎患者症状和体征的持续改善，包括影像学进展率持续较低。《EXCEED研究：头对头比较苏金单抗与阿达木单抗治疗银屑病关节炎疗效的3b期试验》Lancet，2020年5月 (10)EXCEED研究评估了苏金单抗与阿达木单抗作为一线生物单药治疗活动性银屑病关节炎患者的安全性和有效性。这个平行、双盲、多中心、主动对照的3b阶段的研究，招募18岁以上的、活动性银屑病关节炎患者，主要终点是52周时ACR反应标准至少改善20%（ACR20）。研究过程中853例患者完成了52周的研究，研究结束后，苏金单抗组14%和阿达木单抗组24%的患者选择停止使用研究中的治疗方案。第52周时，67%的苏金单抗组患者和62%的阿达木单抗组患者达到治疗的主要终点，两组间无统计学差异。苏金单抗组2%和阿达木单抗组1%的患者出现严重感染，苏金单抗出现一例与研究药物无关的死亡，其他的安全性与之前报道一致。结论：苏金单抗与阿达木单抗的疗效没有统计学差异，但是苏金单抗的治疗保留率更高。《SPIRIT研究：头对头比较依奇珠单抗和阿达单抗治疗银屑病关节炎的疗效和安全性》Annals of Rheumatic Diseases，2020年7月 (11)SPIRIT研究头对头的比较了依奇珠单抗（IL-17A单抗）和阿达单抗治疗银屑病关节炎的有效性和安全性。 研究纳入566例银屑病关节炎的患者，将患者随机分为依奇珠单抗和阿达单抗治疗组，评价标准是24周和52周时，患者ACR反应标准改善50%（ACR50）和银屑病面积和严重度评分改善100%（PASI100）。52周时，依奇珠单抗治疗组中同时达到ACR50和PASI100的患者的比例显著高于阿达木单抗 (39% vs 26%， p
FDA 批准卡那单抗用于治疗成人Still病Lancet 苏金单抗与阿达木单抗治疗银屑病关节炎的头对头比较Arthri & Rheumatol重组腺苷脱氨酶可改善系统性硬化症模型的纤维化卡那单抗（canakinumab）上周一的心脏科专题中，我们聊到了冠心病的抗炎治疗最新进展，目前研究热点集中在IL-1β单克隆抗体卡那单抗和秋水仙碱。今天我们来聊一聊卡那单抗在免疫科中的应用。卡那单抗（canakinumab）最初于2009年被FDA批准用于治疗Cryopyrin相关周期性综合征（CAPS）、全身型幼年特发性关节炎以及三种少见的周期性发热综合征；2020年6月，卡那单抗被FDA批准用于治疗成人Still病。《卡那单抗用于治疗成人Still病以减少关节炎的表现：2期临床试验》Annals of Rheumatic Diseases，2020年8月 (1)这项多中心、双盲、随机、安慰剂对照试验，旨在评价其治疗成人Still病的有效性和安全性。研究纳入19名多关节受累的成人Still病患者，随机给予卡那单抗和安慰剂治疗。基线时，卡那单抗组和安慰剂组的平均疾病活动评分为5.4和5.3。在卡那单抗组中，61%的患者达到30%应答率，50%的患者达到50%应答率，28%的患者达到70%应答率；而对照组仅为20%、6.7%和0%（p=0.033，0.009和0.049)。卡那单抗组的两名患者经历了严重的不良事件。结论：卡那单抗治疗可改善多项成人Still病的疗效指标。银屑病性关节炎银屑病关节炎（psoriatic arthritis，PsA）是一种与银屑病有关的炎症性肌肉骨骼疾病。主要表现为受累关节疼痛和僵硬，可同时累及周围关节和中轴关节，常呈非对称性分布。70%的关节炎就诊时有银屑病病史，80-90%伴有甲病变。实验室检查没有特征性的变化，类风湿因子（RF）、抗核抗体（ANA）和抗瓜氨酸肽抗体（ACPA）大多呈阴性。《荟萃分析：银屑病关节炎关节外表现的患病率》Rheumatology，2020年9月 (2)研究的目的是评价银屑病关节炎关节外症状的流行情况（肌腱炎、指炎、指甲疾病、葡萄膜炎和炎症性肠病），及其对纵向疾病结局的影响。研究纳入65项研究，共计163 299例银屑病关节炎患者。在进行报道的文献中，肌腱炎平均发病率为30%，指炎平均发病率为25%，甲疾病发病率为60%，葡萄膜炎为3.2%，炎症性肠病3.3%。其中，合并指炎的患者影像学进展的可能性增加。结论：银屑病关节炎患者中，常合并肌腱炎、指炎和甲病；而葡萄膜炎和炎症性肠病不常见。《真实世界：银屑病或银屑病关节炎患者严重感染的风险》Annals of Rheumatic Diseases，2020年2月 (3)研究的目的是使用IL-17、IL-12/23或肿瘤坏死因子（TNF）抑制剂，是否与银屑病或银屑病关节炎患者严重感染风险的增加有关。研究共包括11560个新的治疗事件，9264人年的随访。研究共发现190例严重感染（占治疗期的2%），IL-17和TNF抑制剂的感染发生率相似，而IL-12/23抑制剂则明显降低（风险比0.59）。在曾经使用过生物制剂的患者中，各组感染风险无差异。结论：相对于TNF和IL-17抑制剂，IL-12/23抑制剂可以降低银屑病或银屑病关节炎患者的严重感染的风险。《纵向队列研究：银屑病性关节炎的DAPSA、颈动脉斑块和心血管事件》Annals of Rheumatic Diseases，2020年11月 (4)研究的目的是评价反映银屑病关节炎炎症成分的银屑病关节炎的疾病活动评分（DAPSA）是否能够预测心血管事件，而不依赖于传统的心血管危险因素和亚临床颈动脉粥样硬化。研究纳入189例银屑病关节炎患者，平均年龄48.9岁。平均9.9年的随访后，较高的银屑病关节炎的疾病活动评分与心血管事件的风险增加显著相关（风险比 1.04， p=0.009），在多变量模型中调整所有心血管风险后，这种关联仍然有统计学意义。亚组分析中，调整其他心血管风险后，颈动脉斑块与发生CV事件的风险增加显著相关（风险比 3.42）。结论：较高的DAPSA和CP的存在可以独立预测银屑病关节炎患者的心血管事件事件，这种风险不依赖于传统的心血管疾病风险。小羽点评：银屑病性关节炎不仅累及皮肤、关节，还可能增加感染和心血管疾病的发生风险，在临床实践中，需要对银屑病关节炎的患者进行多个系统的功能进行跟踪和随访。银屑病关节炎的治疗银屑病关节炎中，外周关节炎常使用NSAID治疗；若效果不佳，常采用传统改变病情的抗风湿药物（DMARD），如甲氨蝶呤（MTX）、来氟米特（LEF）；若多个关节侵蚀及功能受限，建议使用生物性DMARD，如TNF抑制剂为一线治疗（依那西普、阿达木单抗、英夫利西单抗、塞妥珠单抗和戈利木单抗）。一种TNF抑制剂无效时，可换用另一种TNF抑制剂；两种TNF抑制剂无效时，可使用IL-17抑制剂（苏金单抗、依奇珠单抗）、IL-12/23抑制剂（优特克单抗）、T细胞共刺激调节因子（阿巴西普）、JAK抑制剂（托法替尼）。累及骶髂关节和脊柱关节、附着点炎时，通常不推荐使用传统DMARD。银屑病关节炎患者一般应避免使用糖皮质激素，因为可能增加红皮病或脓疱型银屑病的几率。《回顾性队列研究：传统合成抗风湿药治疗银屑病性关节炎中，单药保留甲氨蝶呤优于柳氮磺胺吡啶》Rheumatology，2020年8月 (5)比较传统合成抗风湿药物的疗效和使用时间的研究有限，此研究的目的是比较一线传统合成抗风湿药物单药治疗的银屑病关节炎的药物保留和药物保留的预测因子。文章回顾性的研究了首次使用传统抗风湿药物作为单一药物治疗银屑病关节炎的187例患者，主要终点是治疗失败、停止用药或添加另一个抗风湿药物的时间。患者中单药使用甲氨蝶呤共163人，单药使用柳氮磺胺吡啶共21人，平均药物保留事件为31.8个月。其中甲氨蝶呤平均使用34.5个月，柳氮磺胺吡啶平均使用12.0个月（P =0.016）。使用甲氨蝶呤的患者中，随着年龄增长药物保留率逐渐增加。治疗失败的主要原因是无效(52%)和副作用(28%)。结论：在临床实践中，甲氨蝶呤单药治疗银屑病关节炎优于柳氮磺胺吡啶。《GO-DACT研究：治疗银屑病关节炎患者的指炎方面，戈利木单抗联合甲氨蝶呤优于单用甲氨蝶呤》Annals of Rheumatic Diseases，2020年4月 (6)戈利木单抗是一种抗肿瘤坏死因子α单抗，研究的目的是评价戈利木单抗联合甲氨碘呤和单用甲氨蝶呤治疗银屑病性关节炎指炎的疗效。这个多中心、随机、双盲、安慰剂对照、平行设计的3b期试验中，银屑病关节炎伴有活动性指炎的患者被分配到戈利木单抗或安慰剂组，两者均与甲氨蝶呤联合使用。24周后，与甲氨蝶呤单药治疗相比，戈利木单抗联合甲氨蝶呤显著改善指炎的临床症状（指炎严重程度评分变化分别为5和2，p = 0.026）。联合治疗组的指炎严重程度评分改善50%或70%的患者和Leeds指炎指数改善20%、50%或70%的患者比例显著高于单用甲氨蝶呤的患者。结论：戈利木单抗联合甲氨蝶呤作为一线生物抗风湿治疗银屑病指炎优于甲氨蝶呤单药治疗。《荟萃分析：生物制剂对银屑病关节炎患者外周关节影像学进展的影响》Rheumatology，2020年11月 (7)研究的目的是确定生物制剂在预防银屑病关节炎患者、外周关节影像学进展中的有效性。研究包括11项临床试验，涉及5382名患者，9种药物和18种治疗方法。与安慰剂相比，接受生物制剂的患者更有可能实现影像学无进展（优势比2.40，其中TNF抑制剂的优势比 2.94，IL抑制剂的优势比 2.15，阿巴西普的优势比 1.54）。生物制剂显著降低了外周关节影像学进展的风险（影像学进展评分平均下降-2.16，其中TNF抑制剂下降 -2.82，IL抑制剂下降 -1.60，阿巴西普下降 -0.40。生物制剂联合甲氨蝶呤的方案，并不优于单一生物制剂治疗的效果；尤特克单抗和苏金单抗的疗效，不受先前抗TNK治疗的影响。结论：与安慰剂相比，生物制剂可能在骨侵蚀和关节间隙狭窄方面延缓银屑病关节炎患者的影像学进展。甲氨蝶呤似乎没有额外的获益；先前的抗肿瘤坏死因子治疗似乎不会影响IL抑制剂的治疗效果。上一次的节目介绍了IL-17抑制剂（苏金单抗、依奇珠单抗）最近刚刚被FDA批准用于治疗中轴型脊柱关节炎，今天来和大家聊一聊IL-17A单抗在银屑病关节炎中的应用，以及比较这两个药物和肿瘤坏死因子抑制剂阿达木单抗的头对头研究。《Future 5研究：苏金单抗治疗银屑病性关节炎的3期研究结果》Rheumatology，2020年6月 (8)研究目的是评估苏金单抗治疗银屑病性关节炎52周后患者的影像学进展。纳入的银屑病性关节炎参与者，既往没有治疗过、或者TNF-α抑制剂无效，被随机分入苏金单抗 300mg组、150mg组、150mg无负荷给药组或安慰剂组，前4周q1w负荷给药，4周后q4w给药。其中300mg组有91.8%的患者52周后，没有出现影像学进展；在150mg组和150mg无负荷给药组中，这里比例分别是85.2%和87.2%。苏金单抗 300mg组、150mg组和150mg无负荷给药组中，影像学vdH-mTSS评分的随机斜率为-0.18、0.11和-0.20。临床疗效持续稳定，52周内没有报告新的或意料之外的安全事件。结论：苏金单抗 300mg、150mg和150mg无负荷剂量组，治疗银屑病性关节炎显示出持续稳定的低进展率。《SPIRIT-P1研究：依奇珠单抗治疗活动性银屑病关节炎患者的III期临床试验3年结果》Rheumatology，2020年2月 (9)研究的目的是评估长达156周的依奇珠单抗（IL-17A单抗）治疗银屑病关节炎的安全性和有效性。银屑病关节炎患者被随机分配到安慰剂组、阿达木单抗或依奇珠单抗q2w或q4w组。在第24周时，阿达木单抗和安慰剂组的患者被重新随机分配到依奇珠单抗q2w或q4w组，并继续延长治疗至第156周，共243例患者完成了为期3年的研究。依奇珠单抗q2w组患者治疗紧急和严重不良事件的发生率分别为38.0%和5.2%，依奇珠单抗q4w组患者为38.1%和8.0%。156周时，两组患者ACR响应≥20%的比例占69.8%和62.5%；响应≥50%的比例为51.8%和56.1%，响应≥70%的比例为33.4%和43.8%。银屑病面积和严重程度指数（PASI）缓解75%的占（63.5%和69.1）；缓解90%的展51.2%和64.5；缓解100%的占43.6%和60.5%。直至156周，在q2w组中的61%和q4w组中的71%的患者，影像学进展得到抑制。结论：依奇珠单抗治疗156周后，其安全性与之前的报道保持一致，并且观察到银屑病关节炎患者症状和体征的持续改善，包括影像学进展率持续较低。《EXCEED研究：头对头比较苏金单抗与阿达木单抗治疗银屑病关节炎疗效的3b期试验》Lancet，2020年5月 (10)EXCEED研究评估了苏金单抗与阿达木单抗作为一线生物单药治疗活动性银屑病关节炎患者的安全性和有效性。这个平行、双盲、多中心、主动对照的3b阶段的研究，招募18岁以上的、活动性银屑病关节炎患者，主要终点是52周时ACR反应标准至少改善20%（ACR20）。研究过程中853例患者完成了52周的研究，研究结束后，苏金单抗组14%和阿达木单抗组24%的患者选择停止使用研究中的治疗方案。第52周时，67%的苏金单抗组患者和62%的阿达木单抗组患者达到治疗的主要终点，两组间无统计学差异。苏金单抗组2%和阿达木单抗组1%的患者出现严重感染，苏金单抗出现一例与研究药物无关的死亡，其他的安全性与之前报道一致。结论：苏金单抗与阿达木单抗的疗效没有统计学差异，但是苏金单抗的治疗保留率更高。《SPIRIT研究：头对头比较依奇珠单抗和阿达单抗治疗银屑病关节炎的疗效和安全性》Annals of Rheumatic Diseases，2020年7月 (11)SPIRIT研究头对头的比较了依奇珠单抗（IL-17A单抗）和阿达单抗治疗银屑病关节炎的有效性和安全性。 研究纳入566例银屑病关节炎的患者，将患者随机分为依奇珠单抗和阿达单抗治疗组，评价标准是24周和52周时，患者ACR反应标准改善50%（ACR50）和银屑病面积和严重度评分改善100%（PASI100）。52周时，依奇珠单抗治疗组中同时达到ACR50和PASI100的患者的比例显著高于阿达木单抗 (39% vs 26%， p
The Journal of Rheumatology's Editor-in-Chief Earl Silverman talks about this month's selection of articles that are most relevant to the clinical rheumatologist. This month's selections include: Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study by Juan D. Cañete, Joan M. Nolla, Ruben Queiro, Miguel J. Rodríguez, Miguel Ruiz and Luis Lizán for the MERECES Working Gro DOI: https://doi.org/10.3899/jrheum.191056 Using Process Improvement and Systems Redesign to Improve Rheumatology Care Quality in a Safety Net Clinic by Alfredo Aguirre, Laura Trupin, Mary Margaretten, Sarah Goglin, Jung Hee Noh and Jinoos Yazdany DOI: https://doi.org/10.3899/jrheum.190472 Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis by Edward P. Stern, Sandra G. Guerra, Harry Chinque, Vanessa Acquaah, David González-Serna, Markella Ponticos, Javier Martin, Voon H. Ong, Korsa Khan, Svetlana I. Nihtyanova, Mark Harber, Aine Burns, Maureen D. Mayes, Shervin Assassi, Carmen Fonseca and Christopher P. Denton DOI: https://doi.org/10.3899/jrheum.190945 Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study by Vincent Langlois, André Gillibert, Yurdagül Uzunhan, Marie-Laure Chabi, Eric Hachulla, Océane Landon-Cardinal, Kuberaka Mariampillai, Nicolas Champtiaux, Hilario Nunes, Olivier Benveniste and Baptiste Hervier DOI: https://doi.org/10.3899/jrheum.190505 Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus by Stanley Moore, Hsin-Hsuan Juo, Christoffer T. Nielsen, Helena Tyden, Anders A. Bengtsson and Christian Lood DOI: https://doi.org/10.3899/jrheum.190875 To read the full articles visit www.jrheum.org Music by David Hilowitz
The Journal of Rheumatology's Editor-in-Chief Earl Silverman talks about this month's selection of articles that are most relevant to the clinical rheumatologist. This month's selections include: Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I) by Marie Skougaard, Henning Bliddal, Robin Christensen, Karen Ellegaard, Sabrina M. Nielsen, Jakub Zavada, Sabina Oreska, Niels S. Krogh, Christian C. Holm, Merete L. Hetland, Jiri Vencovsky, Henrik Røgind, Peter C. Taylor and Henrik Gudbergsen DOI: https://doi.org/10.3899/jrheum.181362 Reasons for the High Cesarean Delivery Rate among Women with Ankylosing Spondylitis: Using the Korean National Health Insurance Database by Jung Sun Lee, Ji Seon Oh, Ye-Jee Kim, Seokchan Hong, Chang-Keun Lee, Bin Yoo and Yong-Gil Kim DOI: https://doi.org/10.3899/jrheum.190754 Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-risk Cohort of Patients with Systemic Sclerosis by Kaitlin A. Quinn, Stephanie R. Wappel, Tunay Kuru and Virginia D. Steen DOI: https://doi.org/10.3899/jrheum.190226 Fibromyalgia Assessment Screening Tool: Clues to Fibromyalgia on a Multidimensional Health Assessment Questionnaire for Routine Care by Kathryn A. Gibson, Isabel Castrejon, Joseph Descallar and Theodore Pincus DOI: https://doi.org/10.3899/jrheum.190277 Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care by Tedi Qendro, María Laura de la Torre, Pantelis Panopalis, Elizabeth Hazel, Brian J. Ward, Inés Colmegna and Marie Hudson DOI: https://doi.org/10.3899/jrheum.181376 To read the full articles visit www.jrheum.org Music by David Hilowitz
Audio abstract for the published article: Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II by Elizabeth R. Volkmann, Donald P. Tashkin, Myung Sim, Ning Li, Dinesh Khanna, Michael D. Roth, Philip J. Clements, Anna-Maria Hoffmann-Vold, Daniel E. Furst, Grace Kim, Jonathan Goldin and Robert M. Elashoff The Journal of Rheumatology October 2019, 46 (10) 1316-1325; DOI: https://doi.org/10.3899/jrheum.180441
Audio abstract of the published article: Venous Thromboembolism in Systemic Sclerosis: Prevalence, Risk Factors, and Effect on Survival by Sindhu R. Johnson, Nabil Hakami, Zareen Ahmad and Duminda N. Wijeysundera The Journal of Rheumatology July 2018, 45 (7) 942-946; DOI: https://doi.org/10.3899/jrheum.170268
The Journal of Rheumatology's Editor-in-Chief Earl Silverman talks about this month's selection of articles that are most relevant to the clinical rheumatologist. This month's selections include: Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale Laure Gossec, Vibeke Strand, Clare Proudfoot, Chieh-I Chen, Sophie Guillonneau, Toshio Kimura, Hubert van Hoogstraten, Erin Mangan and Matthew Reaney DOI: https://doi.org/10.3899/jrheum.180904 Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study John D. Reveille, Atul Deodhar, Paul H. Caldron, Anna Dudek, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H. Leu and Elizabeth C. Hsia DOI: https://doi.org/10.3899/jrheum.180718 Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort Manuel F. Ugarte-Gil, Daniel Wojdyla, Guillermo J. Pons-Estel, Rosana Quintana, José A. Gómez-Puerta, Luis J. Catoggio, Alejandro Alvarellos, Verónica Saurit, Eduardo Borba, Emilia Sato, Lilian Costallat, Nilzio A. Da Silva, Antonio Iglesias-Gamarra, Oscar Neira, Gil Reyes-Llerena, Mario H. Cardiel, Mary Carmen Amigo, Eduardo Acevedo-Vásquez, María H. Esteva-Spinetti, Graciela S. Alarcón and Bernardo A. Pons-Estel DOI: https://doi.org/10.3899/jrheum.180433 Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II Elizabeth R. Volkmann, Donald P. Tashkin, Myung Sim, Ning Li, Dinesh Khanna, Michael D. Roth, Philip J. Clements, Anna-Maria Hoffmann-Vold, Daniel E. Furst, Grace Kim, Jonathan Goldin and Robert M. Elashoff DOI: https://doi.org/10.3899/jrheum.180441 Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis Jean W. Liew and Gregory C. Gardner DOI: https://doi.org/10.3899/jrheum.181018 To read all the full articles visit www.jrheum.org Music by David Hilowitz
In this episode I cover systemic sclerosis and scleroderma.If you want to follow along with written notes on systemic sclerosis and scleroderma go to https://zerotofinals.com/medicine/rheumatology/systemicsclerosis/ or the rheumatology section in the Zero to Finals medicine book.This episode covers the definitions, pathophysiology, presentation, associations, complications, investigations, antibodies and management of systemic sclerosis and scleroderma. The audio in the episode was expertly edited by Harry Watchman.
The Journal of Rheumatology's Editor-in-Chief Earl Silverman talks about this month's selection of articles that are most relevant to the clinical rheumatologist. This months selections include: Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States Zhou Zhou, Yanni Fan, Wenxi Tang, Xinyue Liu, Darren Thomason, Zheng-Yi Zhou, Dendy Macaulay and Aryeh Fischer DOI: https://doi.org/10.3899/jrheum.180445 Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results Arthur N. Lau, J. Carter Thorne, Mohammad Movahedi, Emmanouil Rampakakis, Angela Cesta, Xiuying Li, Sandra Couto, John Sampalis, Claire Bombardier and the OBRI Investigators DOI: https://doi.org/10.3899/jrheum.180486 Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World Mitsumasa Kishimoto, Kazuki Yoshida, Naomi Ichikawa, Hisashi Inoue, Yuko Kaneko, Taku Kawasaki, Kazuo Matsui, Mitsuhiro Morita, Masei Suda, Kurisu Tada, Naoho Takizawa, Naoto Tamura, Atsuo Taniguchi, Yoshinori Taniguchi, Shigeyoshi Tsuji, Yoichiro Haji, Ryo Rokutanda, Haruyuki Yanaoka, Peter P. Cheung, Jieruo Gu, Tae-Hwan Kim, Shue-Fen Luo, Masato Okada, Clementina López Medina, Anna Molto, Maxime Dougados, Shigeto Kobayashi, Désirée van der Heijde and Tetsuya Tomita DOI: https://doi.org/10.3899/jrheum.180412 Pediatric Antibiotic-refractory Lyme Arthritis: A Multicenter Case-control Study Daniel B. Horton, Alysha J. Taxter, Amy L. Davidow, Brandt Groh, David D. Sherry and Carlos D. Rose DOI: https://doi.org/10.3899/jrheum.180775 Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study Pierluigi Macchioni, Carlo Salvarani, Niccolò Possemato, Marwin Gutierrez, Walter Grassi, Stefania Gasparini, Carlo Perricone, Fabio Massimo Perrotta, Rosa Daniela Grembiale, Caterina Bruno, Cesare Tripolino, Marcello Govoni, Giovanni Ciancio, Ilaria Farina, Roberta Ramonda, Paola Frallonardo, Francesca Desiati, Raffaele Scarpa, Luisa Costa, Alen Zabotti, Salvatore De Vita, Rita Maria D'Attino, Giuliana Gualberti, Rocco Merolla, Umberto di Luzio Paparatti, Raffaella Aldigeri and Antonio Marchesoni DOI: https://doi.org/10.3899/jrheum.171411 To read all the full articles visit www.jrheum.org Music by David Hilowitz
Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.
Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.
Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.
Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.
Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.
Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.
This week I'll discuss an important paper in systemic sclerosis, the recent SENSCIS trial that compared 150mg nitedanib to placebo. I wind up coming down pretty hard on this drug; I think it's hype has vastly outpaced its utility. Get the paper itself at ebrheum.com and follow me on @ebrheum to give feedback!
Dr Marwan Bukhari and Prof Christopher Denton, University College London, London, UK, discuss the new BSR and BHPR guidelines for the management of scleroderma and systemic sclerosis. They discuss the key recommendations of these guidelines and the imp
Dr Marwan Bukhari and Prof Christopher Denton, University College London, London, UK, discuss the new BSR and BHPR guidelines for the management of scleroderma and systemic sclerosis. They discuss the key recommendations of these guidelines and the imp
Dr Marwan Bukhari and Prof Christopher Denton, University College London, London, UK, discuss the new BSR and BHPR guidelines for the management of scleroderma and systemic sclerosis. They discuss the key recommendations of these guidelines and the imp
Professor Robert Moots and Professor Marco Matucci Cerinic (University of Florence, Florence, Italy) discuss systemic sclerosis providing an overview of the disease and the different subsets. They review a paper by Gonçalves Marangoni et al and disc
Professor Robert Moots and Professor Marco Matucci Cerinic (University of Florence, Florence, Italy) discuss systemic sclerosis providing an overview of the disease and the different subsets. They review a paper by Gonçalves Marangoni et al and disc
Professor Robert Moots and Professor Marco Matucci Cerinic (University of Florence, Florence, Italy) discuss systemic sclerosis providing an overview of the disease and the different subsets. They review a paper by Gonçalves Marangoni et al and disc
Discussion of the ASSIST trial concerning the potential of stem-cell transplantation for treating systemic sclerosis.
Pulmonary complications of systemic sclerosis are amongst the most challenging to manage. In this podcast, Ulf Mueller-Ladner discusses the current management of these complications with Robert Moots and the potential for a new, more effective therap
Pulmonary complications of systemic sclerosis are amongst the most challenging to manage. In this podcast, Ulf Mueller-Ladner discusses the current management of these complications with Robert Moots and the potential for a new, more effective therap
Pulmonary complications of systemic sclerosis are amongst the most challenging to manage. In this podcast, Ulf Mueller-Ladner discusses the current management of these complications with Robert Moots and the potential for a new, more effective therap
Guest: J. Lee Nelson, MD Host: Michael Benson, MD Fetal cells persisting in maternal tissues for 50 years and then causing a graft versus host reaction? Medicine does not get more bizarre, but this seems to be the case for systemic sclerosis. Dr. Nelson examines the growing evidence to support this new look at some of the "auto-immune" diseases.
© 2020-2025 Ivy Podcast Discovery LLC
